Search

Displaying results 2031 - 2040 of 6951 in total
  1. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    [L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available … [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Ivacaftor

    go.drugbank.com/drugs/DB08820
    ApprovedInvestigational

    [L6841] Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF. … Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals.

  3. Drug

    Rolitetracycline

    go.drugbank.com/drugs/DB01301
    ApprovedWithdrawn

    A pyrrolidinylmethyl tetracycline.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Benzydamine

    go.drugbank.com/drugs/DB09084
    ApprovedInvestigational

    It is used topically for pain relief and anti-inflammatory treatment of the mouth, throat, or muscoskeletal system.

    Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Products for Vaginal Administration
  5. Drug

    Copper gluconate

    go.drugbank.com/drugs/DB11246
    ApprovedInvestigational

    According to the good manufacturing or feeding practice by the FDA, copper gluconate is used as a nutrient or dietary supplement and is generally recognized as safe for use at a level not exceeding 0.005

    Mixtures: Multivitamins and Minerals for Young Women
  6. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

    Categories: Prostacyclin Receptor Agonist, Prostacyclin Receptor Agonists
  7. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    from week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period. … Current available treatments include substitution therapy involving the intravenous administration of standard factor IX once a week for bleeding or as prophylaxis and 2–3 times a week for severe hemophilia

  8. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.

  9. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    [A193029] Recent studies have shown molnupiravir inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Perindopril

    go.drugbank.com/drugs/DB00790
    ApprovedInvestigational

    Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).

    Categories: Antihypertensive Agents Indicated for Hypertension